YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Rhythm Pharmaceuticals, Inc. -- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) -- BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:…
Ultragenyx (RARE) shares ended the last trading session 12.6% higher at $14.5. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 50.9% loss over th…
Stanley Druckenmiller's Duquesne Family Office recently filed its 13F for the second quarter. The firm opened new stakes in more than 40 stocks. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) and Definium Therapeutics, Inc. (NASDAQ:DFTX) are t…
Rhythm Pharmaceuticals, Inc. -- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated improveme…
The Trump administration is expected to announce a series of drug pricing deals with several mid-size biotech companies as early as Monday, adding to similar agreements reached with Big Pharma since late last year, Bloomberg News reported…
Billionaire Stanley Druckenmiller, who runs the Duquesne Family Office hedge fund, has been loading up on healthcare stocks. A year ago, healthcare stocks represented almost 22% of the fund's portfolio. Today, that representation is up to…
Rhythm Pharmaceuticals has delivered very strong long-term share price gains, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. The stock is up about 7x over 5 y…
Rhythm Pharmaceuticals, Inc. -- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination -- BOSTON, Aug. 24, 2026 (…
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are currently the leaders in the weight loss market. Their medicines have proved highly effective and generate billions in annual sales. However, drugs such as Wegovy and Zepbound are inte…
Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by…
Rhythm Pharmaceuticals, Inc. BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroend…
Rhythm Pharmaceuticals, Inc. -- MHRA grants authorization for patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment -- BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals…
Rhythm Pharmaceuticals, Inc. BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroend…
Key Points Interested in Rhythm Pharmaceuticals, Inc.? Here are five stocks we like better. IMCIVREE sales rose 19% sequentially to $71.3 million in Q2 2026, supported by early demand following its U.S. launch for acquired hypothalamic obe…
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.75 per share a year ago. These figures are adjusted for non-recurri…
* Rhythm Pharmaceuticals press release [https://seekingalpha.com/pr/20605381-rhythm-pharmaceuticals-reports-second-quarter-2026-financial-results-and-business-update] (RYTM [https://seekingalpha.com/symbol/RYTM]): Q2 GAAP EPS of -$0.73 bea…
-- U.S. launch of IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- -- Second quarter 2026 net product revenue from global sales…
Rhythm Pharmaceuticals, Inc. -- U.S. launch of IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- -- Second quarter 2026 net produ…
Rhythm Pharmaceuticals, Inc. -- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with setmelanotide and bivamelagon -- -- Management to host conference call to discuss second quarter 2026 financia…
Major earnings expected before the bell on Tuesday include: * Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) * Energy Transfer LP (ET [https://seekingalpha.com/symbol/ET]) * Merck & Co. (MRK [https://seekingalpha.com/symbol/MRK]) * Cat…
The market expects Qiagen (QGEN) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earning…
In early August 2026, Rhythm Pharmaceuticals is scheduled to report quarterly results that analysts expect will show higher revenue but a year-over-year earnings decline, with many anticipating a potential earnings beat versus consensus es…
Rhythm Pharmaceuticals, Inc. (RYTM) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the compa…
Quick Read Over 150 S&P 500 companies report earnings this week, including four Magnificent 7 firms, with futures trading higher heading into peak season. Alphabet (GOOGL) earns a Buy upgrade at Phillip Securities while Stellantis (STLA) s…
Rhythm Pharmaceuticals, Inc. BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroend…
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary duties to share…
Dublin, July 15, 2026 (GLOBE NEWSWIRE) -- The "Oral Obesity Therapies Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Oral Obesity Therapies Market Global Report 2026 provides strategists, marketers, investors…
(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM), announced that results from its pivotal Phase 3 TRANSCEND trial of Setmelanotide in patients with acquired hypothalamic obesity have been published in The New England Journal of Medicine (NE…
Rhythm Pharmaceuticals, Inc. BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroend…
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announ…
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the best biotech stocks on this list. TheFly reported on June 16 that Canaccord analyst Whitney Ij…
Acadia Pharmaceuticals (ACAD) shares rallied 6.8% in the last trading session to close at $25.32. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the s…
Desk setup looking at stocks by LanaStock via iStock As you might have read in some of my past articles, when it comes to Barchart, I was a "long time listener, first time caller."When I started writing here early last year, it was a case…
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the most promising healthcare stocks according to Wall Street analysts. On June 13, Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) shared preliminary results from its ongoing Phase 2 trial o…
(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical readouts spanning therapeutic areas includ…
Rhythm Pharmaceuticals, Inc. -- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years -- -- Bivamelagon therapy achieved progressive reductions in BMI and hunger m…